Gene · 6700
SPRR2A: small proline rich protein 2A
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. SPRR2A: small proline rich protein 2A. Genes, record 6700. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/6700
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P35326 | Small proline-rich protein 2A | 72 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents10
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 63816 | P35326 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 80000 | P35326 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 182971 | P35326 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 10925 | P35326 | Espacenet |
| JP 2019054813 A | 2019-04-11 | 244251 | P35326 | Espacenet |
| JP 2017121241 A | 2017-07-13 | 244251 | P35326 | Espacenet |
| JP 2015516143 A | 2015-06-08 | 244251 | P35326 | Espacenet |
| WO 2012081007 A2 | 2012-06-21 | 32 | P35326 | Espacenet |
| EP 2052088 A2 | 2009-04-29 | 336 | P35326 | Espacenet |
| EP 2052088 A2 | 2009-04-29 | 6704 | P35326 | Espacenet |
Drugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants992
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | SPRR2A papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 11 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 3 | 2025 |
| P20GM103442 | ND INBRE Health & the Environment | 2 | 2025 |
| P30AI094189 | The Johns Hopkins Center for AIDS Research (JHU CFAR) | 2 | 2025 |
| P30CA014089 | University of Southern California Norris Comprehensive Cancer Center Support Grant (CCSG) | 2 | 2025 |
| P30CA015704 | Cancer Center Support Grant | 2 | 2025 |
| P30CA016058 | Cancer Center Support Grant | 2 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 2 | 2025 |
| P30CA056036 | Translational Research in Cancer | 2 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 2 | 2025 |
1 to 10 of 992Source NIH's project files
See all 992 nih grantsPapers1,491
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The effect of toll like receptors in prognosis in patients undergoing radical cystectomy for bladder cancer. | Mol Biol Rep | 2026 | 42667340 | PubTator, text mining | PubMed |
| Integrated Metabolomic and Transcriptomic Profiling Reveals a Distinct Pathological Aging State in Diminished Ovarian Reserve of Advanced Reproductive-Age Women. | Reprod Sci | 2026 | 42426427 | PubTator, text mining | PubMed |
| The SPRR2A-CSTA axis drives IL-17A-induced squamous metaplasia and steroid resistance in allergic rhinitis. | J Allergy Clin Immunol | 2026 | 42269941 | PubTator, text mining | PubMed |
| Single-cell and spatial transcriptomics reveal SPRR2A+ epithelial-MMP1+ fibroblast interactions as key drivers of Esophageal Squamous Cell Carcinoma progression. | Int J Biol Macromol | 2026 | 42173220 | PubTator, text mining | PubMed |
| Multi-omics analysis identified SPRR2D as a potential biomarker for tumor prognosis and immune microenvironment infiltration: a pan-cancer perspective. | Future Sci OA | 2026 | 41933926 | PubTator, text mining | PubMed |
| The Role of B Cells in Tumorigenesis and Immunotherapy. | Immune Netw | 2026 | 41800023 | PubTator, text mining | PubMed |
| Engineering of induced pluripotent stem cells for the efficient development of non-alloreactive, hypoimmunogenic CD8αβ CAR-T cells. | Front Immunol | 2026 | 41798951 | PubTator, text mining | PubMed |
| Dermal Fibroblasts, Not Keratinocytes, Dominate IL-17A/TNF-Driven Inflammation. | Exp Dermatol | 2026 | 41755670 | PubTator, text mining | PubMed |
| Curbing Autoimmunity: A New Fab Fragment Targeting CD40-CD40L Halts B-Cell Activation and Differentiation. | Eur J Immunol | 2026 | 41742604 | PubTator, text mining | PubMed |
| Embolization of a profunda femoris artery injury following battlefield tourniquet application: A case report. | Trauma Case Rep | 2026 | 41717329 | PubTator, text mining | PubMed |
1 to 10 of 1,491
See all 1,491 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/6700
GET https://conductscience.org/api/genes/v1/6700/grants?page=2